The clinical features, diagnosis and classification of dermatomyositis

Journal of Autoimmunity

Volumn 48-49, Issue , 2014, Pages 122-127

  Iaccarino, Luca ^a   Ghirardello, Anna ^a   Bettio, Silvano ^a   Zen, Margherita ^a   Gatto, Mariele ^a   Punzi, Leonardo ^a   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoantibodies; Classification criteria; Connective tissue disease; Dermatomyositis; Idiopathic inflammatory myopathies

Indexed keywords

AUTOANTIBODY; BIOLOGICAL PRODUCT; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE SULFATE; IMMUNOSUPPRESSIVE AGENT; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ARTHRALGIA; ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE CLASSIFICATION; ELECTROMYOGRAPHY; FEVER; FOLLOW UP; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALAISE; MUSCLE BIOPSY; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULE; POIKILODERMA; PRIORITY JOURNAL; RASH; RAYNAUD PHENOMENON; SKIN DEFECT; SKIN MANIFESTATION; WEIGHT REDUCTION;

AUTOANTIBODIES; CLASSIFICATION CRITERIA; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; IDIOPATHIC INFLAMMATORY MYOPATHIES;

AUTOANTIBODIES; CONNECTIVE TISSUE DISEASES; DERMATOMYOSITIS; EXANTHEMA; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MUSCLE, SKELETAL; SKIN DISEASES; ULTRASONOGRAPHY, DOPPLER;

EID: 84895889444     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.11.005     Document Type: Article

References (35)

1. Callen J.P., Wortmann R.L. Dermatomyositis. Clin Dermatol 2006, 24:363-373.
2. Briani C., Doria A., Sarzi-Puttini P., Dalakas M.C. Update on idiopathic inflammatory myopathies. Autoimmunity 2006, 39:161-170.
3. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
4. Zampieri S., Valente M., Adami N., Biral D., Ghirardello A., Rampudda M.E., et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010, 9:449-453.
5. Smoyer-Tomic K.E., Amato A.A., Fernandes A.W. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, medicare supplemental insured, and medicaid enrolled populations: administrative claims analysis. BMC Musculoskelet Disord 2012, 13:103.
6. Mastaglia F.L., Beverley A.P. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis N Am 2002, 28:723-741.
7. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first part). NEngl J Med 1975, 292:344-347.
8. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second part). NEngl J Med 1975, 292:403-407.
9. Euwer R.L., Sontheimer R.D. Dermatologic aspects of myositis. Curr Opin Rheumatol 1994, 6:583-589.
10. Zhang L., Wang G.C., Ma L., Zu N. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 2012, 35:686-691.
11. Iaccarino L., Gatto M., Bettio S., Caso F., Rampudda M., Zen M., et al. Overlap connective tissue disease syndromes. Autoimmun Rev 2013, 12:363-373.
12. Hervier B., Devilliers H., Stanciu R., Meyer A., Uzunhan Y., Masseau A., et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012, 12:2010-2017.
13. Del Grande F., Carrino J.A., Del Grande M., Mammen A.L., Christopher Stine L. Magnetic resonance imaging of inflammatory myopathies. Top Magn Reson Imaging 2011, 22:39-43.
14. Weber M.A. Ultrasound in the inflammatory myopathies. Ann N Y Acad Sci 2009, 1154:159-170.
15. Dalakas M.C. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998, 55:1509-1512.
16. Yuan L., Yao L., Zhao L., Xia L., Shen H., Lu J. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 2013, 31:428-432.
17. Ghirardello A., Zampieri S., Tarricone E., Iaccarino L., Bendo R., Briani C., et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 2006, 39:217-221.
18. Ghirardello A., Zampieri S., Iaccarino L., Tarricone E., Gambari P.F., Doria A. Anti-MI-2 antibodies. Autoimmunity 2005, 38:79-83.
19. Zampieri S., Ghirardello A., Iaccarino L., Tarricone E., Gambari P.F., Doria A. Anti-JO-1 antibodies. Autoimmunity 2005, 38:73-78.
20. Ghirardello A., Bassi N., Palma L., Borella E., Domeneghetti M., Punzi L., et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013, 15:335.
21. Lazarou I.N., Guerne P.A. Classification, diagnosis and management of idiopathic inflammatory myopathies. JRheumatol 2013, 40:550-564.
22. Linklater H., Pipitone N., Rose M.R., Norwood F., Campbell R., Salvarani C., et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013, 31:767-769.
23. Targoff I.N., Miller F.W., Medsger T.A., Oddis C.V. Classification criteria for idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997, 9:527-535.
24. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senecal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005, 84:231-249.
25. Miller F.W., Rider L.G., Plotz P.H., Isenberg D.A., Oddis C.V. Diagnostic criteria for polymyositis and dermatomyositis. Lancet 2003, 362:1762-1763.
26. Amato A.A., Griggs R.C. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003, 61:288-290.
27. Nirmalananthan N., Holton J.L., Hanna M.G. Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheum 2004, 16:684-691.
28. Sontheimer R.D. Dermatomyositis. An overview of recent progress with emphasis on dermatological aspects. Dermatol Clin 2002, 20:387-408.
29. Hoogendijk J.E., Amato A.A., Lecky B.R., Choy E.H., Lundberg I.E., Rose M.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12october 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
30. Danielsson O., Lindvall B., Gati I., Ernerudh J. Classification and diagnostic investigation in inflammatory myopthies: a study of 99 patientes. JRheumatol 2013, 40:1173-1182.
31. Oddis C.V., Rider L.G., Reed A.M., Ruperto N., Brunner H.I., Koneru B., et al. International consensus guidelines for trials of therapies in idiopathic inflammatory myopathies. Arthritis Rheum 2005, 52:2607-2615. International Myositis Assessment and clinical Studies Group.
32. Marie I., Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011, 11:6-13.
33. Choy E., Hoogendijk J., Lecky B., Winer J. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005, 20:CD003643.
34. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012, 11:792-794.
35. Nalotto L., Iaccarino L., Zen M., Gatto M., Borella E., Domenighetti M., et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013, 56:362-370.